QTTB: Bempikibart shows promising efficacy and safety in alopecia areata, with phase III set for next year
Lead asset bempikibart demonstrated strong efficacy and a favorable safety profile in alopecia areata, with a large U.S. market opportunity and plans for a single pivotal phase III trial. Additional indications and dosing regimens are being explored, with robust funding supporting development.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.